
VolitionRx Limited VNRX
$ 2.43
-7.25%
Annual report 2025
added 03-31-2026
VolitionRx Limited General and Administrative Expenses 2011-2026 | VNRX
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses VolitionRx Limited
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9.46 M | 8.49 M | 10.4 M | 10.2 M | 11.7 M | 5.47 M | 4.52 M | 5.78 M | 5.36 M | 5.43 M | 3.9 M | 1.91 M | 1.72 M | 1.3 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 11.7 M | 1.3 M | 6.11 M |
Quarterly General and Administrative Expenses VolitionRx Limited
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.48 M | 2.94 M | 2.24 M | - | 1.82 M | 2.28 M | 2.25 M | - | 2.6 M | 2.64 M | 2.58 M | - | 2.76 M | 3.09 M | 2.6 M | - | 3.14 M | 2.43 M | 1.81 M | - | 1.08 M | 1.51 M | 1.7 M | - | 1.35 M | 1.44 M | 1.23 M | - | 1.45 M | 1.64 M | 1.84 M | - | 1.56 M | 1.43 M | 1.4 M | - | 164 K | 166 K | 228 K | - | 141 K | 122 K | 248 K | - | 129 K | 51.8 K | 68.9 K | - | 68 K | 123 K | 51.6 K | - | 48.2 K | 149 K | 38 K | - | 54.7 K | 45.1 K | 49.9 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.14 M | 38 K | 1.27 M |
General and Administrative Expenses of other stocks in the Diagnostics research industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Burning Rock Biotech Limited
BNR
|
490 M | $ 17.1 | 0.56 % | $ 181 M | ||
|
CareDx, Inc
CDNA
|
108 M | $ 21.5 | 3.32 % | $ 1.15 B | ||
|
Centogene N.V.
CNTG
|
46.7 M | - | -6.23 % | $ 30.6 M | ||
|
Accelerate Diagnostics
AXDX
|
39.2 M | - | -61.36 % | $ 2.46 M | ||
|
Agilent Technologies
A
|
1.62 B | $ 114.52 | -0.86 % | $ 34.8 B | ||
|
Co-Diagnostics
CODX
|
9.06 M | $ 1.55 | - | $ 2.06 M | ||
|
Castle Biosciences
CSTL
|
200 M | $ 24.81 | 1.31 % | $ 689 M | ||
|
Akumin
AKU
|
2.08 M | - | -17.87 % | $ 25.9 M | ||
|
Biocept
BIOC
|
16.1 M | - | -13.05 % | $ 7.29 M | ||
|
Aspira Women's Health
AWH
|
7.96 M | - | -6.19 % | $ 10.5 M | ||
|
Fulgent Genetics
FLGT
|
88.1 M | $ 14.13 | -6.98 % | $ 427 M | ||
|
ICON Public Limited Company
ICLR
|
585 M | $ 112.85 | -4.63 % | $ 9.31 B | ||
|
Chembio Diagnostics
CEMI
|
24.3 M | - | 0.22 % | $ 16.8 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
22.3 M | - | - | $ 562 M | ||
|
Check-Cap Ltd.
CHEK
|
9.46 M | - | - | $ 9.42 M | ||
|
Heska Corporation
HSKA
|
64.1 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
15.8 M | - | -20.0 % | $ 1.06 M | ||
|
Illumina
ILMN
|
1.09 B | $ 135.78 | 7.13 % | $ 21.6 B | ||
|
Lantheus Holdings
LNTH
|
275 M | $ 85.5 | 1.04 % | $ 5.77 B | ||
|
DermTech
DMTK
|
43.8 M | - | -11.32 % | $ 2.94 M | ||
|
Global Cord Blood Corporation
CO
|
187 M | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
97.9 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
3.83 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
126 M | - | 0.12 % | $ 80.1 M | ||
|
Myriad Genetics
MYGN
|
257 M | $ 4.8 | 1.05 % | $ 444 M | ||
|
NeoGenomics
NEO
|
273 M | $ 9.44 | 1.94 % | $ 1.21 B | ||
|
Medpace Holdings
MEDP
|
198 M | $ 417.54 | -0.27 % | $ 12 B | ||
|
National Research Corporation
NRC
|
54.8 M | $ 17.41 | 5.77 % | $ 390 M | ||
|
Charles River Laboratories International
CRL
|
743 M | $ 165.78 | -0.71 % | $ 8.22 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
453 M | - | - | $ 10.7 B | ||
|
Koninklijke Philips N.V.
PHG
|
599 M | $ 26.16 | -0.87 % | $ 20 B | ||
|
Enzo Biochem
ENZ
|
21.7 M | - | -8.98 % | $ 14.8 K | ||
|
Exact Sciences Corporation
EXAS
|
889 M | - | - | $ 19.8 B | ||
|
Guardant Health
GH
|
211 M | $ 87.6 | 0.6 % | $ 11 B | ||
|
Personalis
PSNL
|
46.2 M | $ 5.78 | 4.71 % | $ 342 M | ||
|
Motus GI Holdings
MOTS
|
6.58 M | - | -34.28 % | $ 263 K | ||
|
Interpace Biosciences
IDXG
|
9.48 M | $ 2.12 | 7.07 % | $ 9.38 M | ||
|
Senseonics Holdings
SENS
|
52.5 M | $ 5.1 | -22.84 % | $ 213 M | ||
|
Soleno Therapeutics
SLNO
|
132 M | $ 52.87 | 0.09 % | $ 2.69 B | ||
|
Thermo Fisher Scientific
TMO
|
8.73 B | $ 469.21 | -2.04 % | $ 177 B | ||
|
QIAGEN N.V.
QGEN
|
128 M | - | - | $ 10.6 B | ||
|
Twist Bioscience Corporation
TWST
|
247 M | $ 60.4 | 3.34 % | $ 3.61 B | ||
|
Biomerica
BMRA
|
2.98 M | $ 2.19 | 0.46 % | $ 5.03 M | ||
|
Laboratory Corporation of America Holdings
LH
|
2.22 B | $ 255.84 | -0.37 % | $ 21.3 B | ||
|
Celcuity
CELC
|
27.2 M | $ 125.65 | 3.54 % | $ 5.88 B | ||
|
Natera
NTRA
|
589 M | $ 207.28 | 0.54 % | $ 20.4 B | ||
|
Neogen Corporation
NEOG
|
218 M | $ 9.53 | 1.38 % | $ 2.07 B | ||
|
Invitae Corporation
NVTA
|
192 M | - | - | $ 21.2 M | ||
|
Waters Corporation
WAT
|
240 M | $ 307.12 | -0.68 % | $ 18.3 B | ||
|
Quest Diagnostics Incorporated
DGX
|
1.97 B | $ 192.67 | -0.79 % | $ 21.4 B |